SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: March 3, 2003
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation develops generic formulation of
diabetes drug Glucotrol XL(r ) for Watson Pharmaceuticals
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: March 5, 2003
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Exhibit (a)
Contacts:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2440
Email: rick.stewart@amarincorp.com
Stefan Ohlsson
Managing Director
Amarin Development AB
Phone +46 (0)40 539801
stefan.ohlsson@amarindev.se
AMARIN CORPORATION DEVELOPS GENERIC FORMULATION OF DIABETES
DRUG GLUCOTROL XL (r ) FOR WATSON PHARMACEUTICALS
LONDON, United Kingdom, March 5, 2003: Amarin Corporation plc
(NASDAQ: AMRN) today confirmed that its Swedish subsidiary, Amarin
Development AB, has developed a generic formulation of glipizide extended
release tablets, as part of an agreement with Watson Pharmaceuticals, Inc.
Glipizide extended release tablets are marketed in the United States under
the trade name Glucotrol XL (r ) by Pfizer, Inc. Watson announced on 27th
December 2002 that it has filed an Abbreviated New Drug Application (ANDA)
with the U.S. Food and Drug Administration seeking approval to market its
generic version of Glucotrol XL (r ) tablets 5 mg and 10 mg.
"This collaboration with Watson Pharmaceuticals demonstrates Amarin's
capability of developing technically challenging products such as generic
Glucotrol XL (r ). The Watson collaboration, plus other collaborations,
including Tanabe for morphine in Japan, demonstrate the strength of
Amarin's product development capability," said Rick Stewart, chief
executive officer of Amarin.
Glucotrol XL (r ) (glipizide extended release tablets) is indicated as
an adjunct to diet for the control of hyperglycemia in patients with type-2
diabetes. Pfizer reported U.S. Glucotrol XL (r ) sales of approximately
$265 million for the twelve months ending September 30, 2002.
Amarin Corporation, plc is a specialty pharmaceutical company focused
on neurology and pain management. The company plans to become a leader in
these therapeutic categories by providing innovative products and solutions
that address significant unmet medical needs. Amarin has eleven
pharmaceutical products on the US market along with a development pipeline
that includes two late-stage candidates: Zelapar (tm ) (selegiline orally
disintegrating tablets), for Parkinson's disease and LAX-101, a proprietary
compound for Huntington's Disease.
For press releases and other corporate information, visit our website
at
http://www.amarincorp.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from
any performance suggested herein. Such risks and uncertainties include,
without limitation, risks associated with the inherent uncertainty of
pharmaceutical
research, product development and commercialization, the impact of
competitive products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more information,
please refer to Amarin Corporation's Annual Report for 2001 on Form 20-F
and its Form 6-Ks as filed with the U.S. Securities and Exchange
Commission. The Company assumes no obligation to update information on its
expectations.